 CNS Pharmaceuticals, Inc., Nasdaq: CNSP CNS or the Company, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation ODD for its lead product Berubicin for the treatment of malignant gliomas. 